The Exocrine Pancreatic Insufficiency Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Exocrine Pancreatic Insufficiency Market?
The Exocrine Pancreatic Insufficiency Global Market Report 2025 shows a positive growth trend with the market size expanding from $2.59 billion in 2024 to $2.76 billion in 2025, translating to a compound annual growth rate (CAGR) of 6.6%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Exocrine Pancreatic Insufficiency Industry?
The exocrine pancreatic insufficiency market is predicted to reach $3.58 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.7%.
Download Your Free Sample of the 2025 Exocrine Pancreatic Insufficiency Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Exocrine Pancreatic Insufficiency Market?
The key drivers in the exocrine pancreatic insufficiency market are:
• Continued increase in awareness and screening
• Expanding geriatric population and rising incidence of chronic diseases
• Improvements in patient access to healthcare and advancements in digestive health research
• Development and expansion of digital health solutions and regulatory advances
Global Market Segmentation: Identifying Major Exocrine Pancreatic Insufficiency Industry Segments
The exocrine pancreatic insufficiency market covered in this report is segmented –
1) By Treatment: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Other Treatments
2) By Diagnosis: Imaging Tests, Computed Tomography (CT) Scan, Abdominal Ultrasound, Secretin Pancreatic Function Test, Fecal Fat Test, Fecal Elastase Test (FE-
1), Other Types
3) By Symptoms: Abdominal Pain, Constipation, Diarrhea, Fatty Stools, Weight Loss, Other Symptoms
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End Users: Hospitals, Specialty Clinics, Homecare
Pre-order the 2025 Exocrine Pancreatic Insufficiency Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Exocrine Pancreatic Insufficiency Market?
The key trends in the exocrine pancreatic insufficiency market are:
• The increasing use of telehealth and digital health solutions is shaping the future of the market.
• More emphasis is being placed on collaborative research initiatives in the industry.
• The attention towards pediatric exocrine pancreatic insufficiency is emerging as a significant trend.
• Regulatory advances and fast-track designations are influencing the market dynamics.
Who Are the Top Competitors & Leading Players in the Exocrine Pancreatic Insufficiency Market?
Major companies in the exocrine pancreatic insufficiency market are:
• Pfizer Inc.
• F. Hoffmann-La Roche AG
• Merck & Co. Inc.
• Janssen Pharmaceuticals Inc.
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Sanofi S.A.
• AstraZeneca PLC
• Medtronic PLC
• Eli Lilly and Company
• Gilead Sciences Inc.
• Nestle Health Science S.A.
• Allergan PLC
• Chiesi Farmaceutici S.p.A.
• Wockhardt Ltd.
• Amryt Pharma PLC
• Codexis Inc.
• Nordmark Arzneimittel GmbH & Co. KG
• Aimmune Therapeutics Inc.
• Digestive Care Inc.
• Enzymedica Inc.
• Vivus Inc.
• Alcresta Therapeutics Inc.
• Cilian AG
• Perseo Pharma AG
• Enzyme Development Corporation
• First Wave BioPharma Inc.
• Synspira Therapeutics
Regional Dominance: Which Area Leads the Global Exocrine Pancreatic Insufficiency Market?
North America was the largest region in the exocrine pancreatic insufficiency market in 2024
